Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial

Abstract Background Relapsed or refractory follicular lymphoma (rrFL) is an incurable disease associated with shorter remissions and survival after each line of standard therapy. Many promising novel, chemotherapy-free therapies are in development, but few are licensed as their role in current treat...

Full description

Bibliographic Details
Main Authors: Graham McIlroy, Siân Lax, Charlotte Gaskell, Aimee Jackson, Malcolm Rhodes, Tania Seale, Sonia Fox, Lousie Hopkins, Jessica Okosun, Sally F. Barrington, Ingo Ringshausen, Alan G. Ramsay, Maria Calaminici, Kim Linton, Mark Bishton
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Cancer
Subjects:
Clinical trial
Relapsed follicular lymphoma
Bayesian power prior methodology
Adaptive design
Epcoritamab
Lenalidomide
Online Access:https://doi.org/10.1186/s12885-024-12112-0

Internet

https://doi.org/10.1186/s12885-024-12112-0

Similar Items